Pharmaceutical Executive August 19, 2024
The acquisition will allow Lilly to add Morphic’s IBF treatment to its pipeline.
Eli Lilly and Company successfully completed its acquisition of Morphic Holding, Inc, a biopharmaceutical company focused on integrin therapies for chronic diseases.1 Lilly will add Morphic’s assets to its pipeline, including MORF-057, a treatment for inflammatory bowel disease (IBF).
Lilly agreed to purchase all issued and outstanding shares of Morphic’s stock for $57 a share.
In a press release, Lilly’s chief scientific officer and president of Lilly Research Laboratories and Lilly Immunology Daniel Skovronsky, MD, PhD, said, “We are committed to exploring innovative approaches for immunologic diseases and believe Morphic’s pipeline holds promise in improving outcomes and expanding treatment options for people with devastating conditions like IBD....
Today's Sponsors
Today's Sponsor